BioCentury | Aug 17, 2018
Finance

Location, location, biotech

...majority stake. The second, renal cancer candidate CM082 (vorolanib; X-82), was developed by Maryland biotech Tyrogenex Inc....
...South San Francisco, Calif. Jihe Group Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tyrogenex Inc....
BioCentury | Sep 1, 2017
Company News

Betta, Tyrogenex form JV for RCC candidate

...and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's...
...CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex...
...Pharmaceuticals Co. Ltd. (SZSE:300558), Hangzhou, China Tyrogenex Inc. , Rockville, Md. Business: Cancer Chris Lieu vorolanib X-82 Betta Pharmaceuticals Co. Ltd. Tyrogenex Inc. Platelet...
BioCentury | Aug 28, 2017
Company News

Betta, Tyrogenex form JV for RCC candidate

...and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's...
...CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex...
...colorectal cancer drug Vectibix panitumumab, a mAb against EGFR , in China. Chris Lieu vorolanib X-82 Betta Pharmaceuticals Co. Ltd. Tyrogenex Inc. Platelet...
BioCentury | Mar 14, 2017
Clinical News

Vorolanib: Completed Ph II APEX Study enrollment

...anti-VEGF drug as needed. The anti-VEGF drugs include Eylea aflibercept, Lucentis ranibizumab and Avastin bevacizumab. Tyrogenex Inc....
...for the duration of the study and safety Status: Completed Phase II enrollment Milestone: NA Nora Weintraub X-82 Tyrogenex Inc. Platelet...
BioCentury | Jun 20, 2016
Clinical News

X-82: Phase I data

...of Medicine. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Tyrogenex Inc....
BioCentury | Nov 23, 2015
Clinical News

X-82: Phase I final data

...anti-VEGF therapy. Data were presented at the American Academy of Ophthalmology meeting in Las Vegas. Tyrogenex...
...BioCentury, May 18). X-82 is in the Phase II APEX trial to treat wet AMD. Tyrogenex Inc....
BioCentury | May 18, 2015
Clinical News

X-82: Preliminary Phase I data

...meeting in Denver. X-82 is in the Phase II APEX trial to treat wet AMD. Tyrogenex Inc....
BioCentury | May 11, 2015
Clinical News

X-82: Phase II started

...plus Eylea aflibercept as needed in 132 patients who have been previously treated with Eylea. Tyrogenex Inc....
BioCentury | Apr 1, 2015
Company News

Management tracks

...cancer play Xcovery Holding Co. LLC (West Palm Beach, Fla.) and oncology and opthalmology company Tyrogenex Inc....
...Fla.). Snyder, who co-founded both companies, will remain chairman at Xcovery and a director at Tyrogenex...
BioCentury | Jun 23, 2014
Financial News

Tyrogenex completes venture financing

Tyrogenex Inc. , West Palm Beach, Fla. Business: Cancer, Ophthalmic Date completed: 2014-06-19 Type: Venture financing Raised: Not disclosed Investor: Brace Pharmaceuticals Inc. Note: The company raised an undisclosed amount in a tranched $15 million series...
Items per page:
1 - 10 of 11
BioCentury | Aug 17, 2018
Finance

Location, location, biotech

...majority stake. The second, renal cancer candidate CM082 (vorolanib; X-82), was developed by Maryland biotech Tyrogenex Inc....
...South San Francisco, Calif. Jihe Group Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tyrogenex Inc....
BioCentury | Sep 1, 2017
Company News

Betta, Tyrogenex form JV for RCC candidate

...and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's...
...CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex...
...Pharmaceuticals Co. Ltd. (SZSE:300558), Hangzhou, China Tyrogenex Inc. , Rockville, Md. Business: Cancer Chris Lieu vorolanib X-82 Betta Pharmaceuticals Co. Ltd. Tyrogenex Inc. Platelet...
BioCentury | Aug 28, 2017
Company News

Betta, Tyrogenex form JV for RCC candidate

...and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's...
...CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex...
...colorectal cancer drug Vectibix panitumumab, a mAb against EGFR , in China. Chris Lieu vorolanib X-82 Betta Pharmaceuticals Co. Ltd. Tyrogenex Inc. Platelet...
BioCentury | Mar 14, 2017
Clinical News

Vorolanib: Completed Ph II APEX Study enrollment

...anti-VEGF drug as needed. The anti-VEGF drugs include Eylea aflibercept, Lucentis ranibizumab and Avastin bevacizumab. Tyrogenex Inc....
...for the duration of the study and safety Status: Completed Phase II enrollment Milestone: NA Nora Weintraub X-82 Tyrogenex Inc. Platelet...
BioCentury | Jun 20, 2016
Clinical News

X-82: Phase I data

...of Medicine. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Tyrogenex Inc....
BioCentury | Nov 23, 2015
Clinical News

X-82: Phase I final data

...anti-VEGF therapy. Data were presented at the American Academy of Ophthalmology meeting in Las Vegas. Tyrogenex...
...BioCentury, May 18). X-82 is in the Phase II APEX trial to treat wet AMD. Tyrogenex Inc....
BioCentury | May 18, 2015
Clinical News

X-82: Preliminary Phase I data

...meeting in Denver. X-82 is in the Phase II APEX trial to treat wet AMD. Tyrogenex Inc....
BioCentury | May 11, 2015
Clinical News

X-82: Phase II started

...plus Eylea aflibercept as needed in 132 patients who have been previously treated with Eylea. Tyrogenex Inc....
BioCentury | Apr 1, 2015
Company News

Management tracks

...cancer play Xcovery Holding Co. LLC (West Palm Beach, Fla.) and oncology and opthalmology company Tyrogenex Inc....
...Fla.). Snyder, who co-founded both companies, will remain chairman at Xcovery and a director at Tyrogenex...
BioCentury | Jun 23, 2014
Financial News

Tyrogenex completes venture financing

Tyrogenex Inc. , West Palm Beach, Fla. Business: Cancer, Ophthalmic Date completed: 2014-06-19 Type: Venture financing Raised: Not disclosed Investor: Brace Pharmaceuticals Inc. Note: The company raised an undisclosed amount in a tranched $15 million series...
Items per page:
1 - 10 of 11